The DOI matches its Crossref record.
Flavonoids as DNA Topoisomerase Antagonists and Poisons: Structure-Activity Relationships
Open accessAbstract
Selected flavonoids were tested for their ability to inhibit the catalytic activity of DNA topoisomerase (topo) I and II. Myricetin, quercetin, fisetin, and morin were found to inhibit both enzymes, while phloretin, kaempferol, and 4',6,7-trihydroxyisoflavone inhibited topo II without inhibiting topo I. Flavonoids demonstrating potent topo I and II inhibition required hydroxyl group substitution at the C-3, C-7, C-3', and C-4' positions and also required a keto group at C-4. Additional B-ring hydroxylation enhanced flavonoid topo I inhibitory action. A C-2, C-3 double bond was also required, but when the A ring is opened, the requirement for the double bond was eliminated. Genistein has been previously reported to stabilize the covalent topo II-DNA cleavage complex and thus function as a topo II poison. All flavonoids were tested for their ability to stabilize the cleavage complex between topo I or topo II and DNA. None of the agents stabilized the topo I-DNA cleavage complex, but prunetin, quercetin, kaempferol, and apigenin stabilized the topo II DNA-complex. Competition experiments have shown that genistein-induced topo II-mediated DNA cleavage can be inhibited by myricetin, suggesting that both types of inhibitors (antagonists and poisons) interact with the same functional domain of their target enzyme. These results are of use for the selection of flavonoids that can inhibit specific topoisomerases at specific stages of the topoisomerization reaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Review on the Dietary Flavonoid Kaempferol
M. Calderon-Montano, J., Burgos-Moron, E., Perez-Guerrero, C., & Lopez-Lazaro, M. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711795305335 · Cited by 1,383
Phyto-oestrogens and Western Diseases
Adlercreutz, H., & Mazur, W. (1997) · Annals of Medicine · doi:10.3109/07853899709113696 · Cited by 1,279
Dietary agents in cancer prevention: flavonoids and isoflavonoids
Birt, D. F., Hendrich, S., & Wang, W. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00137-1 · Cited by 1,171
Myricetin: A Dietary Molecule with Diverse Biological Activities
Semwal, D., Semwal, R., Combrinck, S., & Viljoen, A. (2016) · Nutrients · doi:10.3390/nu8020090 · Cited by 707
How relevant are flavonoids as antioxidants in plants?
Hernández, I., Alegre, L., Van Breusegem, F., & Munné-Bosch, S. (2009) · Trends in Plant Science · doi:10.1016/j.tplants.2008.12.003 · Cited by 703
Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450
Hodek, P., Trefil, P., & Stiborová, M. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00285-x · Cited by 649
Role of plant polyphenols in genomic stability
Ferguson, L. R. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00073-2 · Cited by 596
Flavonoids as prospective compounds for anti-cancer therapy
Ravishankar, D., Rajora, A. K., Greco, F., & Osborn, H. M. I. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.10.004 · Cited by 572
Potential health impacts of excessive flavonoid intake
Skibola, C. F., & Smith, M. T. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00304-x · Cited by 569
Polyphenols and glutathione synthesis regulation
Moskaug, J. Ø., Carlsen, H., Myhrstad, M. C., & Blomhoff, R. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.277s · Cited by 494
Isoflavones: estrogenic activity, biological effect and bioavailability
Vitale, D. C., Piazza, C., Melilli, B., Drago, F., & Salomone, S. (2013) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-012-0112-y · Cited by 490
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Comalada, M., Ballester, I., Bailón, E., Sierra, S., Xaus, J., Gálvez, J., Medina, F. S. D., & Zarzuelo, A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.016 · Cited by 440
Properties and applications of flavonoid metal complexes
Kasprzak, M. M., Erxleben, A., & Ochocki, J. (2015) · RSC Advances · doi:10.1039/c5ra05069c · Cited by 432
Characterization of quercetin binding site on DNA gyrase
Plaper, A., Golob, M., Hafner, I., Oblak, M., Šolmajer, T., & Jerala, R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01006-4 · Cited by 369
Nguyen, T. T. T. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh052 · Cited by 344
Antiproliferative Activity of Flavonoids on Several Cancer Cell Lines
KAWAII, S., TOMONO, Y., KATASE, E., OGAWA, K., & YANO, M. (1999) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.63.896 · Cited by 334
Biological effects of myricetin
Ong, K. C., & Khoo, H.-E. (1997) · General Pharmacology: The Vascular System · doi:10.1016/s0306-3623(96)00421-1 · Cited by 292
Busby, M. G., Jeffcoat, A. R., Bloedon, L. T., Koch, M. A., Black, T., Dix, K. J., Heizer, W. D., Thomas, B. F., Hill, J. M., Crowell, J. A., et al. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.1.126 · Cited by 262
Morin: A Promising Natural Drug
Caselli, A., Cirri, P., Santi, A., & Paoli, P. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160106150821 · Cited by 253
Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite
Touil, Y. S., Auzeil, N., Boulinguez, F., Saighi, H., Regazzetti, A., Scherman, D., & Chabot, G. G. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.097 · Cited by 111
(2002) · PubMed · Cited by 74
Metadata
- Authors
- Constantinou, A., Mehta, R., Runyan, C., Rao, K., Vaughan, A., & Moon, R.
- Venue
- Journal of Natural Products
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-02
- Volume
- 58
- Issue
- 2
- Pages
- 217-225
- ISSN
- 0163-3864 (ISSN-L)
- 1520-6025
- OpenAlex
- W2035925517
- Cited by
- 275
- References
- 0
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.